Inhibikase Therapeutics (IKT) director Berman received 68,968 Stock Option (Right to Buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Dennis N Berman (director at Inhibikase Therapeutics Inc., IKT) reported that they received 68,968 Stock Option (Right to Buy) on Jan 21, 2025.
- Reporting person
- Berman Dennis N
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | Grant or award (A) | Stock Option (Right to Buy)On 68,968 Common Stock1, 2, 3, ... | +68,968 | - | - | 30,000 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 30,000 direct
Footnotes from the filing
- 1. The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.
- 2. The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
- 3. The transactions reported herein reflect an option repricing (the Repricing ) effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- 4. This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Berman report in this IKT Form 4?
Dennis N Berman (director at Inhibikase Therapeutics Inc., IKT) reported that they received 68,968 Stock Option (Right to Buy) on Jan 21, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for IKT
Earlier insider filings at IKT
- Feb 20, 2025SEC Form 4 filed by Director Berman Dennis N
- Jan 22, 2025SEC Form 4 filed by Director Berman Dennis N
- Jan 22, 2025SEC Form 4 filed by Director Freeman Roy Lester
- Jan 22, 2025SEC Form 4 filed by President and CEO Werner Milton H.
- Jan 22, 2025SEC Form 4 filed by Chief Financial Officer Lees-Rolfe Garth
Quantisnow market dataNASDAQ
IKT
Inhibikase Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Get push alerts for IKT
Full IKT profile on Quantisnow Follow IKT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time